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Summary
HIV-positive adolescents face a number of
challenges in dealing with their disease and its
treatment. In this qualitative study, twenty-nine
HIV-positive adolescents aged 13 to 20 years (22
girls), who live in Switzerland, were asked, in a
semi-structured interview (duration of 40–110
minutes), to describe their perceptions and experi-
ences with the disease itself and with therapeutic
adherence.While younger adolescents most often
thought of their disease as fate, older adolescents
usually knew that they had received it through
vertical transmission, although the topic appeared
to be particularly difficult to discuss for those liv-
ing with their HIV-positive mothers. Based on
their attending physician’s assessment, 18 subjects
were judged highly adherent, 4 fairly and 7 poorly
adherent. High adherence appeared linked with
adequate psychological adjustment and effective
coping mechanisms, as well as with the discussion
and adoption of explicit medication-taking strate-
gies. The setting and organisation of health care
teams should allow for ongoing discussions with
HIV-positive adolescents that focus on their per-
ceptions of their disease, how they cope with it and
with the treatment, and how they could improve
their adherence.
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coping strategies; treatment; therapeutic adherence
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Introduction
Adolescence is a complex developmental pro-
cess that includes the progressive adoption of
autonomy and identity [1, 2]. Like other individuals
suffering from chronic conditions, HIV-positive
adolescents undergoing highly active antiretroviral
treatment (HAART) face a number of challenges
related to these two developmental tasks [3–5]. On
one hand,HIV-positive adolescents have to develop
their identity, a sense of personal sameness and con-
tinuity paired with some belief in the meaning of
their life and their role in the community [1]. HIV-
positive adolescents have to integrate the fact that
they are not as “normal” as their peers, that they
have to take medication, and they have to accept life
in a context of uncertainty about whether they will
survive and for how long [6, 7]. Thus, beyond pro-
viding the medical follow-up for the HIV infection,
health professionals caring for these young people
must assist them in developing their autonomy as
well as a stable identity by discussing the impact of
the disease and its treatment on their everyday lives
[8, 9].
On the other hand, as they progressively strive
to gain their autonomy, which can be reflected in
their capacity to manage their treatment without
parental/other caring adults’ support, it is inevitable
at times that their adherence to treatment weakens
[10–14]. The risk of low adherence is increased by
the fact that anHIV infection is often“silent”mean-
ing that, contrary to asthma or rheumatic disease,
not taking medication is not immediately followed
by observable consequences [15, 16].
To shed further light on the situation of these
adolescents, a qualitative study was designed focus-
ing on their health, lifestyle, treatment adherence
and psychosocial characteristics. The objective of
this paper is to describe the adolescents’ perceptions
of their illness, of their therapeutic adherence and of
their participation in decisions regarding their treat-
ment, with the idea that a better understanding by
health professionals of these perceptions will assist
them in improving the outcomes, both in terms of
the adolescents’ coping capacities and how to im-
prove adherence to treatment.
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In Switzerland,most adolescents suffering fromHIV
infections have acquired it vertically. They are treated by
paediatricians specialized in infectious diseases – usually
in university-based hospitals – who regularly meet to dis-
cuss treatment issues and to participate in research within
the Swiss Mother and Child HIV cohort study, the Mo-
CHiV [17]. Criteria for eligibility for this study were age
(12 to 20 years), any type of HIV infection, no severe
mental retardation, fluency in either French or Swiss Ger-
man and knowledge of one’s diagnosis. The target num-
ber of participants was set at around 30 because it was felt
that the most common representations and issues could
be covered with this number. Of the seven identified
treatment centers, six agreed to participate: the team from
the Inselspital (Bern) said they had no time to be involved.
Among 55 (40 girls) eligible adolescents, three did not
know their diagnosis, three were considered unable to
give valid answers due to mental retardation and the oth-
ers could not be reached and were thus excluded from the
selection. Among the 42 potential participants, 29 adoles-
cents were randomly selected and interviewed (22 fe-
males). The Ethics Committee of each participating hos-
pital reviewed and accepted the study protocol. Subjects
signed an informed consent form before the interview.All
parents or adoption/foster parents of under-age adoles-
cents (<18 years) were informed about the study and for
those under the age of 16 years, the parents’ formal writ-
ten approval was obtained, in accordance with the ethical
and legal framework in Switzerland.
A single bilingual interviewer (RT), a psychologist
with experience in the field of aids/HIV, performed all in-
terviews. He was not part of the health care team and was
unknown to the subjects until the day of the interview.
The encounter, which was totally confidential, lasted an
average of one hour (40 to 110 minutes) in French or
Swiss-German depending on the patient. The interview
was based on a guided semi-structured schedule and cov-
ered several broad issues.These topics were first discussed
with some of the physicians in charge of the patients and
then with two HIV positive adolescents with whom the
interview was pre-tested. All interviews were tape re-
corded and anonymously transcribed verbatim.The inter-
views in Swiss-German were translated into French by
the interviewer to facilitate analysis by the largely French-
speaking study team. Using the principles of grounded
theory [18], the main investigators (JCS, JJC, RT& PAM)
had several encounters to identify and discuss the central
themes and issues emerging from the content of the inter-
views, which were reviewed several times without the as-
sistance of specialized software. Content analysis identi-
fied several categories of answers related to the selected
topics of this article. Also, at the time the interviews took
place, physicians were asked to rate the therapeutic adher-
ence of their young patients on a ten points scale from
poor (one) to excellent [10], based on the clinical course
and the lab tests. A coding system permitted the authors
to match each interview with this rating.
2World Health
Organization, WHO
Case Deﬁnitions of
HIV for Surveillance
and Revised Clinical
Staging and
Immunological
Classiﬁcation of
HIV-related disease
in Adults and
Children, August 7,
2006. Available
at http://www.
womenchildrenhiv.
org/wchiv?page=
charts-00-02
Methods
Results
Description of the sample
Table 1 provides some background character-
istics of the sample.A third of the subjects (N = 10)
came fromAfrica or South America, some of them
having been adopted by Swiss parents or living
with foster parents.While the majority of subjects
suffered from a proven vertically acquired infec-
tion, the information was missing for four subjects
adopted during infancy. None of the participants
had been infected during adolescence as a result of
unsafe sex or injecting drugs. As shown on table 2,
the vast majority of subjects were under medica-
tion, although the treatment for one boy and two
girls had been discontinued because of poor ad-
herence or refusal. Eleven adolescents had never
had any complications of their infection (clinical
stages 1) while 18 had experienced at least one
symptom, either earlier or at the time of the inter-
view (clinical stages 2–4)
2
.
Perceptions of the disease: a developmental
perspective
Younger adolescents (<16 years) had a con-
crete vision of their disease.They knew that it was
a transmissible infection; they mentioned the risk
of a drop of blood or they had heard of a virus.
However, no one could give an explanation of
what this illness was, giving such explanations as,
“Maybe I once heard about CD4 or viremia, but it
doesn’t mean anything to me…. I come here every
month. They take blood… There are drugs that enter
through a tube” (girl, 13 years). “My parents call
them little soldiers, the CD4, but frankly, when they say
that everything is fine, I don’t really understand what
it means” (girl, 14 years). Most older adolescents
gave the impression of having been able to inte-
grate what their disease was and what it meant to
them: A 15-year-old girl who had researched the
web by herself said: “Wow, you ask me what I
know…HIV is the virus and if it increases in the blood,
Girls
N = 22
Boys
N =7
Total
N = 29
Vertical transmission 18 7 25
No information on transmission 4 0 4
12–15 years of age 10 2 12
16–20 years of age 12 5 17
In school 17 3 20
Apprenticeship 3 2 5
Unemployed/untrained
1 2
3
Employed 1 0 1
Live with two biological parents 1 0 1
Live with one biological parent 10 3
13
Live with adoptive family 5 1 6
Live in foster home/foster family 3 2 5
Live alone or with roommates 3 1 4
Table 1
Selected background
characteristics of the
sample.
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Girls
N = 22
Boys
N = 7
Total
N = 29
No clinical manifestation (stage 1)
#
8 3 11
At least one clinical manifestation
(stages 2–4)
#
14 4 18
Currently on HAART 20 6 26
No current treatment 2 1 3
1–2 consultations a year 0 1 1
2–3 consultations a year 1 0 1
3–4 consultations a year 13 2 15
>4 consultations a year 8 4 12
Excellent/good adherence
(perfectly/well compliant)*
14 4 18
Intermediate adherence
(“fairly” compliant)
3 1 4
Poor adherence (“poorly” compliant)
§
5 2 7
#
World Health Organization,WHO Case Definitions of HIV
for Surveillance and Revised Clinical Staging and Immunological
Classification of HIV-related disease in Adults and Children,
August 7, 2006. Available at
http://www.womenchildrenhiv.org/wchiv?page=charts-00-02
* as graded from very poor to excellent by the physician in
charge of the patient, using both clinical and lab information
§
including one boy and two girls for which treatment has been
discontinued (poor adherence/refusal)
Table 2
Selected clinical
characteristics of the
sample, including
the assessment
of therapeutic
adherence by
the physician.
then you get AIDS, your immune system fails and you
can get all kinds of infections”. An 18-year-old girl re-
ported, “I’ve known about my disease since I was six,
but somewhere around age thirteen or fourteen I real-
ized its importance and impact on my life…. You know,
that’s the age one falls in love…,well, actually that’s ad-
olescence”. An 18-year-old boy disclosed, “It’s impor-
tant to think about my disease when planning my fu-
ture… but I don’t know how long I will live”. Some
participants seemed to have an attitude of denial or
rebellion. For instance, when asked about the im-
portance of her infection in her life, a 19-year-old
girl responded “No importance at all… it’s as if I
hadn’t anything wrong….Well, I really have nothing”.
Exchanging questions, ideas and feelings
about one’s disease: a difficult task
The majority of subjects indicated that they
had not discussed much how they had been in-
fected, neither with their physician nor with their
parents. That seemed to be the case particularly
for youngsters living with anHIV-positive mother.
A young girl stated, “I am HIV-positive since my
birth…. My mother… got the infection… when
she was young [but] we have never discussed this
together”. A 15-year-old girl living with her HIV-
positive mother commented, “One day, maybe
when I was twelve, my mother said to me, ‘Look
you have to listen to me…’ and she explained what
I had…. She was afraid how I would react…, that
I would probably hate her…. I don’t want to dis-
cuss this with her because I see it can hurt her; in
fact... she has burst into tears so often, asking,
‘Why did I give you this illness?’”. An 18-year-old
girl with several HIV-positive persons in her fam-
ily, in addition to her mother, didn’t even seem to
know exactly the origin of her infection: “When I
was 12 years old, I asked my mother why I had to
take that [medication]….Then she told me… that
she also had it... maybe before she got married, but
she didn’t know…. I don’t know how I was in-
fected”.
Medication taking: from parent’s control to
autonomous choice of strategies
The younger patients depended on the par-
ents to take the role of reminders. For several
young subjects, the only reason for not taking
medication was because of forgetting, usually un-
der special circumstances: “Last time I missed…
we were with friends away from home” (13-year-
old girl). Older adolescents (>15 years) described
more personal strategies: “I have a little box with
my medication in it, that I keep with me…. It is a
routine I don’t forget” (17-year-old boy); “It’s the
first thing I do when I wake up…” (19-year-old
boy). Some mentioned the use of cell phones or
alarm-clocks: “I put reminders onmy cell-phone…
since I use it twice a minute, I simply can’t forget,
it’s clear” (16-year-old girl). Some put post-it
notes on mirrors and others put their pills in the
chocolate box they use for their breakfast.
Developing specific strategies becomes in-
creasingly important as the adolescent grows older
and goes away from home more often, participat-
ing in parties or camps or being invited to stay
overnight elsewhere. The majority of the subjects
report that they don’t reveal their condition to
their friends and consequently take their medica-
tion secretly. Thus, a 15-year-girl reported, “At
school, I used to go to the toilets…. Swallowing
the tablets doesn’t take much time”. Other older
adolescents had developed more automatic strate-
gies and taking the medication outside one’s home
seemed to have become a routine: “I always have
pills with me… I have tablets in my pocket… I ask
for a drink, even at a bar and I quickly swallow the
pill” (18-year-old girl). A few adherent subjects
seem to have overcome the difficulty of swallow-
ing medication in the presence of friends. For ex-
ample, a 15-year-old boy reported, “When I was
younger, my father used to advise the parents
when I would sleepover at a friend’s home….
Later, I used to go to the toilet, but now if I stay
with friends I know, I don’t do it secretly”.
Interestingly, those participants who were less
explicit about their strategies appeared to have a
lower adherence rate. For instance, a 13-year-old
girl with intermediate adherence said, “I don’t have
any real strategy, it’s just my mother who reminds me”;
another non-adherent 17-year-old girl reported,
“No, it comes naturally; I just tell myself that I
shouldn’t miss it”. Some younger adolescents didn’t
seem able to anticipate how to deal with the issue
of medication taking when left alone with this re-
sponsibility: two 14-year-old girls questioned
about any kind of strategy they could imagine to
remember to take their pills answered that they
had never thought about it.
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Therapeutic adherence: linked with attitudes
towards the disease
Table 2 displays the therapeutic adherence
rating according to the doctors. Most subjects
were rated as very adherent with their treatment
(>7 on the scale), while 4 out of 29 were rated as
intermediate (5–7 on the scale) and 7 as poorly
adherent (<5 on the scale). Although medication
taking among adherent subjects seemed to have
become a part of their existence, it was still not
perceived as a real routine. For instance, a 16-year-
old girl reported, “I am happy to have medications;
thanks to them, my viremia is low… but on the other
hand, when you feel so well, then you don’t always want
to bother about taking them regularly…. I admit that
taking my medication has never been an automatism; I
have to force myself, even now”. An 18-year-old fe-
male subject also said, “Taking medication is just…
it’s just shit”. Some mature respondents brought
more abstract reasons for being adherent. For in-
stance, a 16-year-old girl reported: “I am, however,
very careful because the medication is very expensive….
The price keeps me from forgetting; at least as far as I
am concerned… not taking them is like throwing
money out the window”.
In general, the adherence rate reported by the
physician appeared to be lower among older ado-
lescents (>15 years) in comparison with younger
subjects: while the mean rating among 12 to 15
year old was 8.3, it was only 6.2 among those
16 years and older. Additionally, it appeared that
those with a low adherence rate had developed an
attitude of rebellion or denial towards their dis-
ease. A 17-year-old girl reported, “Having medica-
tion taking as the center of one’s life is just a pity” and
another 18-year-old girl disclosed, “I was in charge
of my medication… and shit… I wanted to be normal;
I wanted not to have to think about it all the time”.
The presence of side effects was never mentioned
as a cause of poor adherence.
The role of doctor-patient relationship in the
treatment
With some nuances, all our respondents ex-
cept one expressed how good their relationship
with their doctor was. However, although the
overall feeling about the quality of the relationship
with the physician was good, the nature of this re-
lationship and how the issue of treatment was
tackled (doses, frequency, type and number of
medications) seemed to vary from one situation to
another, from a fairly paternalistic type to a more
collaborative one.This was independent of the age
of the respondent, but was probably more as a re-
sult of the pattern of communication used by the
physicians. Several – mostly adherent – adoles-
cents reported being involved in the discussion
about their treatment. For instance, a 17-year-old
girl stated, “I do make suggestions… everything
I want to say, I say… and then my doctor says yes….
I once proposed to take my pills differently and he
agreed”. Nevertheless, several patients said that
they did not really have something to say about
the nature of their treatment, and some would
even hide the problem they faced, in terms of ther-
apeutic adherence, from their doctors. For in-
stance, a poorly compliant 14-year-old girl said,
“Once I was vomiting every time and my mother sug-
gested I should stop taking my pills…. Of course, we
didn’t say anything to the doctor”. A non-adherent
16-year-old boy declared “Tssss.. they have always
chosen my medication for me…. I just had to follow
orders”.
Discussion
The results reported in this paper were drawn
from a study of twenty-nine HIV positive adoles-
cents who all knew their diagnoses and had under-
gone or were currently undergoing HAART. To
our knowledge, our research is one of the first in-
depth qualitative studies conducted in Europe on
a substantial clinical sample of HIV-infected ado-
lescents. Our careful assurance of confidentiality
and respect of ethical guidelines allowed these ad-
olescents to express themselves quite openly and
sincerely, lending insight to their individual per-
ceptions, attitudes and behaviours regarding their
conditions.
Regarding the sample, there were more girls
than boys, as is the case within the entire Swiss
MoCHiV cohort.We do not know to what extent
this is due to chance or if it reflects a greater vul-
nerability of male children to the HIV infection,
who may have died earlier from their disease, as
suggested in other publications [19, 20]. Only one
out of the 29 participants lived with both biologi-
cal parents, while a third of the subjects’ mothers
had died and one out of five patients was an
adopted child. Such family patterns are closely
linked to the fact that most of the HIV-positive
children and adolescents in Switzerland have been
infected vertically by an HIV-positive mother, in
contrast with the situation in other countries
where many adolescents contract their disease
through sexual intercourse or intravenous drug
use [21–23].
Contrary to the findings of a qualitative study
of Canadian adolescents [24], the adolescents of
this study appeared to be fairly well oriented about
the nature of their disease and treatment. Several
patients reported, however, that the specifics of
their condition were not discussed with their par-
ents much and some of them had actually resorted
to the internet for information. Most of the sub-
jects living with an infected mother expressed how
difficult it was to raise this topic with her, given
the guilt, torn loyalties and emotional dilemmas it
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inevitably evoked [25–27]. Younger adolescents
considered their condition as a kind of fate, appar-
ently living with the disease without reflecting on
its meaning to them or on how they had acquired
it. This absence of in-depth reflection may be at-
tributed to the pattern of concrete thinking that is
characteristic of early adolescence or, as found in a
qualitative study run in Africa, may be linked, for
some orphan subjects, to a difficulty in overcom-
ing the bereavement they face [27]. Older adoles-
cents, who were developmentally more capable of
abstract thinking, tended to see their condition
less as fate and more as an infection they had re-
ceived through the transmission of a virus from
their mothers. Other insights gained from the in-
terviews also underscored the importance of effec-
tive communication between health professionals
and HIV infected adolescents. Given the apparent
difficulties for these patients to talk openly about
their disease and their condition, health profes-
sionals should be encouraged to undertake explor-
atory discussion with infected adolescents as well
as with the families, in spite of the strong emotions
of fear, sadness, or guilt which may ensue. This is
particularly needed when a parent is also living
with an HIV infection, as questions pertaining to
the source of transmission of the disease appears
to be highly emotional and difficult to approach
[27, 28]. The phenomenon observed in this study
in which some older adolescents progressively re-
jected their disease and treatment needs to be an-
ticipated from the very beginning of adolescence,
and those subjects (and their families) who have
difficulties in accepting their condition should be
offered early psychological support [29].
Three quarters of our subjects were consid-
ered by their physicians to be highly compliant
with their treatment regime (table 2). The rating
achieved in our sample, based on lab tests and the
physicians appraisal, is somewhat higher than that
self-reported in two USA-based studies of youths
in the same age range [30, 31] and much higher
still than another USA-based survey of 32 adoles-
cents (13–21 years) of whom 78% were judged
non-compliant [13], as assessed by a review of the
patients’ charts. However, in a recent quantitative
study from Ethiopia, the non adherence rate over
the last seven days, as reported by parents among
a sample of 390 subjects (half children/half adoles-
cents) was as low as 13% [32]. One has to recog-
nize the difficulty linked with any comparison in
this field, since both the size, age range and adher-
ence measurement differ greatly from one study to
another.
While the results suggest that most of our
older subjects could integrate their disease with
the development of self, a few exhibited an atti-
tude of refusal or denial of their condition that ap-
peared to result in low adherence. This finding is
consistent with a study focusing on identity devel-
opment among HIV positive teenagers [6]. A Bel-
gian study of HIV positive children also linked ad-
herence to personal psychological attributes and
coping strategies (e.g., denial versus acceptance)
with the authors concluding that “coping with
HIV and the process of establishing good adher-
ence may be interrelated” [33].
Although a progressive assumption of respon-
sibility for taking one’s medication properly
belongs to the process of increasing autonomy
during late adolescence, the drop in adherence
observed in some older adolescents may suggest
they have not been prepared to take over this task
adequately [12, 34]. The account of two 14 year-
old girls who could not imagine coping with their
treatment without the oversight of their parents
underlines the importance that health providers
also anticipate the younger adolescent’s acquisi-
tion of autonomy and its impact on adherence
[15], raising the discussions of self-management as
it becomes developmentally appropriate. Actually,
many of our participants offered creative ideas to
ensure or improve their own adherence, a finding
that could encourage health professionals to sys-
tematically ask these adolescents for their own
views and solutions, thereby augmenting their pa-
tients’ sense of autonomy and preparing them to
manage medication on their own.
In a similar way, the results suggested that ad-
herence was linked with the kind of relationship
established with the health care provider. Some
subjects vividly described how they were able to
find new adherence strategies when openly dis-
cussing with their physicians about how to im-
prove the situation.The reverse is true as well: the
fact that some subjects would hide their episodes
of non adherence from their doctors appeared re-
lated to the fact that these physicians offered a
more paternalistic kind of relationship in which
the adolescents felt they would be judged instead
of being helped. Even some of those subjects who
claimed to have good relationships with their doc-
tors did not always admit to missing medication.
Although this is probably inevitable to some de-
gree, improved provider communication grounded
in a non-judgemental, non-paternalistic attitude
may positively affect therapy adherence.
Many of the limitations of this study may be
attributed to its qualitative and cross sectional na-
ture, which does not allow for firm causal relation-
ship and inferences to be gained, regarding the
link between various personal and environmental
factors and the attitudes and behaviours of the
participants. The comparisons of the compliance
ratings observed in the current study with those of
other studies are tempered by the fact that al-
though our measure was based on laboratory tests
and clinical characteristics, it was qualitative and
does not perfectly reflect the amount of missed
medication. There is also the possibility that the
adolescents excluded from the target population
(N = 13) may have a higher rate of poor adher-
ence. Additionally, we cannot assume that the in-
terviews reflect the whole range of attitudes and
behaviours among HIV-positive adolescents, con-
sidering that about half of the adolescents living
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with HIV in Switzerland were not included in the
sample.
Based on our results, practical recommenda-
tions are suggested for professionals treating HIV-
positive adolescents that could help improve the
quality of life of these adolescents and their adher-
ence to treatment. Firstly, they should foster an
open discussion of the infection with patients and
their families, while allowing for the exploration
of the underlying emotional dimension, especially
among those in which the mother is also infected.
Secondly, in an attempt to improve adherence
rate, they should inquire directly about it and en-
courage patients to propose their own solutions to
improve it. Finally, they should anticipate the po-
tential problems of denial and rebellion which can
arise during the adolescent process, especially with
those patients in the earlier stages of adolescence.
Although this probably applies to any adolescent
with a chronic condition, the fact that the HIV in-
fection is often not symptomatic among these
young people makes it more difficult to take med-
ication without being able to feel any positive ef-
fect on their health.
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Annex: Semi-structured questionnaire (main questions, not necessarily
addressed in this order)
Your family: Who do you live with? How
would you define your relationship with your par-
ents/guardians? How would you define the rela-
tionship with your siblings? Are there conflicts in
your family?
Your lifestyle: Overall, do you think that your
health is good? During the last 30 days, have you
used any of the following substances…? Do you
have a boy/girl friend? Have you ever had sexual
intercourse? How many partners have you had in
the last year? What kind of contraception do you
or your partner use? Does he/she know about
your disease? Have there been times when you
have not used a condom? If yes à how many
times? What are the reasons for not saying about
your disease?
The disease: Who knows about your disease?
What do you know about your condition? When
did you learn that you were positive? Can you ex-
plain what the terms “viremia”, “CD4” or “viral
load” mean?
The treatment: Please describe your treat-
ment.When and where is it more difficult to take
your medication? What are the strategies you use
to take your medication when you are not at
home? Are there any strategies you use to remind
yourself that you need to take your medication?
Are there strategies that you think might help you
in taking your medication (even if you have not
tried them yet)? Are there pills/doses that you did
not take yesterday? Howmany?What are the rea-
sons for not taking the pills/doses? What would
make it easier to take your medication?Apart from
the medication prescribed by your doctor, are you
taking any other medications/alternative therapies
(in the broader sense)? Which ones? Why? Do
they help?
Your life: Do you have a best friend? Does he/
she know about your disease? Do you currently
study, work or both? How is your schooling/work
going? How is the relationship with your teach-
ers/employers? Do they know about your disease?
Do you have friends at school/work? Do they
know about your disease?What do you usually do
on week-end or during your leisure time?
The health system: How would you rate your
relationship with your health care team? What
would be the things in this relationship that you
would like to change or improve? What are the
things in this relationship that you really appreci-
ate? What are the things (if any) that you do not
discuss with your doctor but you would like to dis-
cuss? What are the issues (if any) that you do not
bring up to your doctor/team?Why?
